Today's top medical abstracts
Oncology
Become a Member Today!
Email
Password
Remember me
Forgot your Password?

Invite Code?

Home
General Oncology
For Practicing
Oncologists
Conferences
Jobs
Newsletters
My Library
Topics in
Oncology
        Alternative Therapies
        Anemia/Polycythemia
        BMT/SCT
        Basic Science/Genetics
        Bone/Cartilage
        Breast
        Carcinogenesis
        Coagulation/Bleeding Dz
        Colorectal Cancer/Polyps
        Dermatologic Oncology
        Diagnostics/Radiology
        Economics of Medicine
        Endocrine Oncology
        GI Oncology
        Gynecologic Oncology
        Head and Neck
        Hepatobiliary/Pancreas
        Leukemia/Lymphoma
        Lung/Thoracic Oncology
        Myeloproliferative Dz
        Neurologic Oncology
        Pain/Palliative Care
        Pediatric Heme/Oncology
        Pharmacology/Therapy
        Popular Press
        Renal/Urologic
        Side Effects
        Soft Tissue/Sarcoma
        Transfusion Medicine
 
Help
Resource Center
RSS News Feeds
Send Newsletter
to a Friend
 
Sponsor
For Practicing Oncologists
Technology Advances: Next-Generation Diagnostics Offer On-the-Spot Results
Dorothy J. Schirf, MD, MDLinx Oncology
Off-Label Use: Sitting In Limbo
Roberta Buell, MBA, Sausalito Healthcare Partners
Clinical Trial Watch: Trial Finds Virtual Colonoscopy Comparable to Standard Colonoscopy
Tracy Hampton, PhD, MDLinx Oncology
  See all
oropharyngeal cancer;indicators of response Article Summary

Click the title below to leave the MDLinx Network and go to the Journal's Website
EGFR, p16, HPV titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer
Journal of Clinical Oncology, 07/03/08
Print     Email This Article     Save in My Library   Free Abstract
Kumar B et al. - In a study to prospectively identify markers of response to therapy and outcome in an organ-sparing trial for advanced oropharyngeal cancer, it was shown that low epidermal growth factor receptor (EGFR) and high p16 (or higher human papillomavirus [HPV] titer) expression are markers of good response to organ-sparing therapy and outcome, whereas high EGFR expression, combined low p53/high Bcl-xL expression, female sex, and smoking are associated with a poor outcome

Methods
  • Pretreatment biopsies were examined for expression of EGFR, p16, Bcl-xL, and p53 as well as for p53 mutation
  • These markers were assessed for association with high-risk HPV, response to therapy, and survival
  • Pt variables included smoking history, sex, age, primary site, tumor stage, and nodal status

Results
  • EGFR expression was inversely associated with response to induction chemotherapy (IC), chemotherapy/radiotherapy (CRT), overall survival (OS), and disease-specific survival (DSS) and was directly associated with current smoking, female sex, and lower HPV titer
  • HPV titer was significantly associated with p16 expression; p16 was significantly associated with response to IC, CRT, OS, and DSS
  • As combined markers, lower HPV titer and high EGFR expression were associated with worse OS and DSS
  • In 36 of 42 biopsies, p53 was wild-type, and only 1 HPV-positive tumor had mutant p53
  • Combination of low p53 and high Bcl-xL expression was associated with poor OS and DSS

Sponsor
Read a Different Specialty
Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT
Family Medicine
Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology
Orthopedics
Pediatrics
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology
Profession Index
Dentist
Hospital Administrator
Nurse
    Medical Students
Nurse Practitioner
Pharma/Drug Marketer
    Pharmacist
Physician
Physician Assistants
Article Search
Keyword:
Search:
Published within:
Sort By:
Date Relevance
    
Sponsor
Sponsor
About MDLinx  |  Contact  |  Advertise with MDLinx  |  Site Map  |  Privacy Policy  |  Terms of Use  |  Sign Up For Newsletters  |  Recommend this Site

English |  Español |  Français |  Deutsch |  中文 |  Руccкий |  Norsk |  Nederlands |  Português |  Italiano

©1999-2008 MDLinx, Inc.